Background:
It is not known whether childhood cancer survivors (CCS) develop human papillomavirus (HPV)-associated malignancies more frequently than the general population.
Methods:
We assessed the cumulative incidence of SMN in sites typically associated with HPV (HPV-SMN) and evaluated Standardized Incidence Ratios (SIR) using age-, sex-and calendar-year specific rates from the Surveillance, Epidemiology and End Results (SEER) program. Multivariate Cox regression models identified associations between key risk factors and HPV-SMN development.
Results: Among 27,620 CCS, 42 developed an HPV-SMN at a median age of 28 years (range: 8-42) and a median of 16 years (range: 5-30) after their primary cancer. The 30-year cumulative incidence of an HPV-SMN was 0.25% (95% confidence interval [CI]: 0.16%-0.34%). HPV-SMN locations included oral cavity/pharynx (N=26, 62%), rectum (N=10, 21%), cervix/uteri (N=3, 7%), and vulva (N=3, 7%). The incidence of HPV-SMN was over 2-fold higher among CCS than the general population (SIR=2.54, 95% CI 1.8-3.6) with an absolute excess risk (AER) of 6.5/100,000 person-years. Rates were elevated in those exposed (SIR=3.02, CI 2.01-4.53) and not exposed to radiotherapy (RT; SIR=2.19, CI 1.21-3.95). Risk of oral cavity/pharynx SMN was elevated in both those exposed (SIR=7.26, CI 3.87-13.64) and not exposed (SIR=4.23, CI 2.20-8.12) to head or neck RT, whereas, risk in GU locations was elevated in those exposed (SIR=4.04, CI 2.10-7.78) but not in those not exposed to pelvic RT (SIR=0.77, CI 0.34-1.71). Male sex (RR=2.7, CI 1.4-5.5), exposure to head/neck/pelvic RT (RR=2.1, CI 1.0-4.3), platinum chemotherapy (RR=5.0, CI: 2.2-11.1), and alkylating agents (RR=3.1, CI 1.0-9.2) increased the risk. Survivors with an HPV-SMN were more likely to be deceased than those without (40.8% vs. 12.7%, p<0.01); 11/17 (65%) of deceased cases died of their SMN.
Conclusions:
While the overall incidence is low, CCS are at increased risk for developing malignancies in locations commonly associated with HPV infection in the
